Joseph Boss, MD
Uveitis and Ocular Inflammatory Disease · Grand Rapids, MINPI 1912346388
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.3%), consulting fees and ownership interests — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Alimera Sciences, Inc. at 38.4% of the total. Reporting peaked in 2020 at $5,507 and has fallen 84.8% since, to $839 in 2025.
Across 168 payments — averaging $114.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$7K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
- Eyepoint US, Inc.$2K
- US Retina LLC$2K
- Regeneron Healthcare Solutions, Inc.$733
- Bausch & Lomb Americas Inc.$604
- plus $2K from 14 others
Across 10 payments — averaging $3777.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eyepoint US, Inc.$21K
- Alimera Sciences, Inc.$15K
- ANI Pharmaceuticals, Inc.$2K
What the payments were for
- Consulting fees$6,87036%
- Food & beverage$10,80056%
- Ownership interest$1,5178%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 30 | $7,361 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $5,455 |
| Eyepoint US, Inc. | 8 | $1,762 |
| US Retina LLC | 3 | $1,517 |
| Regeneron Healthcare Solutions, Inc. | 30 | $733 |
| Bausch & Lomb Americas Inc. | 24 | $604 |
| Apellis Pharmaceuticals, Inc. | 16 | $365 |
| AbbVie(2 entities) | 8 | $263 |
| ANI Pharmaceuticals, Inc. | 9 | $247 |
| Genentech USA, Inc. | 6 | $167 |
| Coherus Oncology, Inc. | 3 | $148 |
| Novartis | 2 | $137 |
| Biogen | 6 | $114 |
| Mallinckrodt Hospital Products Inc. | 3 | $62 |
| Amgen | 3 | $60 |
| Mallinckrodt Enterprises LLC | 2 | $55 |
| Astellas Pharma US Inc | 2 | $55 |
| Harrow Eye, LLC | 1 | $36 |
| Biotissue Holdings Inc. | 2 | $31 |
| Dompe US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few uveitis and ocular inflammatory disease providers in Michiganto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $78,613 |
| Difluprednate | 135 | $12,811 |
| Prednisolone Acetate | 299 | $10,747 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $2,957 |
| Timolol Maleate | 188 | $2,161 |
| ValacyclovirValacyclovir Hcl | 48 | $1,995 |
| Brimonidine Tartrate | 146 | $1,633 |
| Dorzolamide Hcl | 66 | $1,403 |
| Gentamicin Sulfate | 100 | $798 |
| Latanoprost | 58 | $720 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $712 |
| Prednisone | 79 | $589 |
| Acetazolamide | 14 | $248 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.